{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:04:00Z","timestamp":1781849040556,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Research Initiative in Substance Misuse","award":["CIS-144301"],"award-info":[{"award-number":["CIS-144301"]}]},{"name":"Canadian Research Initiative in Substance Misuse","award":["CIS-144302"],"award-info":[{"award-number":["CIS-144302"]}]},{"name":"Canadian Research Initiative in Substance Misuse","award":["CIS-144303"],"award-info":[{"award-number":["CIS-144303"]}]},{"name":"Canadian Research Initiative in Substance Misuse","award":["CIS-144304"],"award-info":[{"award-number":["CIS-144304"]}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["SMN-139148"],"award-info":[{"award-number":["SMN-139148"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["SMN-139149"],"award-info":[{"award-number":["SMN-139149"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["SMN-139150"],"award-info":[{"award-number":["SMN-139150"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","award":["SMN-139151"],"award-info":[{"award-number":["SMN-139151"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cct.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T20:49:42Z","timestamp":1522961382000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale"],"prefix":"10.1016","volume":"69","author":[{"given":"M. Eugenia","family":"Socias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Ahamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bruneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Cameron","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17\u201318","key":"10.1016\/j.cct.2018.04.001_bb0005","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1503\/cmaj.160356","article-title":"Effective Canadian policy to reduce harms from prescription opioids: learning from past failures","volume":"188","author":"Fischer","year":"2016","journal-title":"CMAJ"},{"issue":"17\u201318","key":"10.1016\/j.cct.2018.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1503\/cmaj.160554","article-title":"An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders","volume":"188","author":"Socias","year":"2016","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.cct.2018.04.001_bb0015","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.17269\/cjph.105.4143","article-title":"Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later","volume":"105","author":"Fischer","year":"2014","journal-title":"Can. J. Public Health"},{"key":"10.1016\/j.cct.2018.04.001_bb0020","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu. Rev. Public Health"},{"issue":"12","key":"10.1016\/j.cct.2018.04.001_bb0025","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/add.13479","article-title":"Adopting the 'cascade of care' framework: an opportunity to close the implementation gap in addiction care?","volume":"111","author":"Socias","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2018.04.001_bb0030","series-title":"A Guideline for the Clinical Management of Opioid Use Disorder","year":"2017"},{"issue":"2","key":"10.1016\/j.cct.2018.04.001_bb0035","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cct.2018.04.001_bb0040","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","volume":"5","author":"Nielsen","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cct.2018.04.001_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.cct.2018.04.001_bb0050","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.drugpo.2015.04.015","article-title":"An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: structural barriers and public health potential","volume":"26","author":"Perlman","year":"2015","journal-title":"Int. J. Drug Policy"},{"issue":"Suppl. 1","key":"10.1016\/j.cct.2018.04.001_bb0055","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study","volume":"56","author":"Altice","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"8","key":"10.1016\/j.cct.2018.04.001_bb0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/QAD.0000000000000642","article-title":"The causal effect of opioid substitution treatment on HAART medication refill adherence","volume":"29","author":"Nosyk","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cct.2018.04.001_bb0065","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.cct.2018.04.001_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J. Addict. Dis."},{"issue":"5","key":"10.1016\/j.cct.2018.04.001_bb0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/02791072.2014.921743","article-title":"Patient perspectives on buprenorphine\/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study","volume":"46","author":"Teruya","year":"2014","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.cct.2018.04.001_bb0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.cct.2018.04.001_bb0085","article-title":"Supervised dosing with a long-acting opioid medication in the management of opioid dependence","volume":"4","author":"Saulle","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cct.2018.04.001_bb0090","unstructured":"Canadian Research Initiative in Substance Misuse (CRISM). http:\/\/www.cihr-irsc.gc.ca\/e\/44597.html. (Accessed August 18 2017)."},{"issue":"5","key":"10.1016\/j.cct.2018.04.001_bb0095","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","article-title":"A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers","volume":"62","author":"Thorpe","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"8","key":"10.1016\/j.cct.2018.04.001_bb0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0021-9681(67)90041-0","article-title":"Explanatory and pragmatic attitudes in therapeutical trials","volume":"20","author":"Schwartz","year":"1967","journal-title":"J. Chron. Dis."},{"key":"10.1016\/j.cct.2018.04.001_bb0105","series-title":"Alberta Methadone Maintenance Treatment Standards and Guidelines for Dependence","year":"2014"},{"key":"10.1016\/j.cct.2018.04.001_bb0110","series-title":"Buprenorphine\/Naloxone for Opioid Dependence - Clinical Practice Guideline","year":"2011"},{"key":"10.1016\/j.cct.2018.04.001_bb0115","series-title":"Methadone Maintenance Treatment Program Standards and Clinical Guidelines","year":"2011"},{"key":"10.1016\/j.cct.2018.04.001_bb0120","series-title":"La bupr\u00e9norphine dans Le traitement de la d\u00e9pendance aux opio\u00efdes","year":"2009"},{"key":"10.1016\/j.cct.2018.04.001_bb0125","series-title":"Utilisation de la m\u00e9thadone dans le traitement de la toxicomanie aux opiac\u00e9s","year":"1999"},{"issue":"9","key":"10.1016\/j.cct.2018.04.001_bb0130","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.cct.2018.04.001_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000086396","article-title":"The client satisfaction questionnaire: psychometric properties in a Dutch addict population","volume":"11","author":"De Wilde","year":"2005","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.cct.2018.04.001_bb0140","series-title":"Treatment Entry Questionnaire (TEQ) Version 1.0, Users Guide","author":"Wild","year":"1999"},{"issue":"3","key":"10.1016\/j.cct.2018.04.001_bb0145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1037\/0278-6133.17.3.269","article-title":"Autonomous regulation and long-term medication adherence in adult outpatients","volume":"17","author":"Williams","year":"1998","journal-title":"Health Psychol."},{"issue":"3","key":"10.1016\/j.cct.2018.04.001_bb0150","first-page":"21","article-title":"The control preferences scale","volume":"29","author":"Degner","year":"1996","journal-title":"Can. J. Nurs. Res."},{"issue":"1","key":"10.1016\/j.cct.2018.04.001_bb0155","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.2196\/jmir.3085","article-title":"The psychometric properties of CollaboRATE. A fast and frugal patient-reported measure of the shared decision-making process","volume":"16","author":"Barr","year":"2014","journal-title":"J. Med. Internet Res."},{"issue":"10","key":"10.1016\/j.cct.2018.04.001_bb0160","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual. Life Res."},{"issue":"10","key":"10.1016\/j.cct.2018.04.001_bb0165","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jclinepi.2009.12.003","article-title":"The quality of eight health status measures were compared for chronic opioid dependence","volume":"63","author":"Nosyk","year":"2010","journal-title":"J. Clin. Epidemiol."},{"issue":"5","key":"10.1016\/j.cct.2018.04.001_bb0170","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890109002092","article-title":"The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies","volume":"33","author":"Furlong","year":"2001","journal-title":"Ann. Med."},{"issue":"2","key":"10.1016\/j.cct.2018.04.001_bb0175","first-page":"129","article-title":"Pain assessment: global use of the brief pain inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann. Acad. Med. Singap."},{"issue":"1","key":"10.1016\/j.cct.2018.04.001_bb0180","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","article-title":"The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties","volume":"68","author":"Fals-Stewart","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.cct.2018.04.001_bb0185","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.cct.2018.04.001_bb0190","unstructured":"J.S. Cacciola, A.T. Mclellan, A.I. Alterman, F.D. Mulvaney, A comparison of a self-administered ASI with the standard ASI interview, Problems of Drug Dependence, 1997, Proceedings of the 59th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. NIH Publication no. 98\u00b14305 (1998)."},{"key":"10.1016\/j.cct.2018.04.001_bb0195","series-title":"Manual for the Beck Depression Inventory-II","first-page":"82","volume":"1","author":"Beck","year":"1996"},{"key":"10.1016\/j.cct.2018.04.001_bb0200","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2018.04.001_bb0205","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1017\/S0033291702006074","article-title":"Colpe, e. al, short screening scales to monitor population prevalences and trends in non-specific psychological distress","volume":"32","author":"Kessler","year":"2002","journal-title":"Psychol. Med."},{"key":"10.1016\/j.cct.2018.04.001_bb0210","series-title":"Risk Behavior Assessment","author":"National Institute on Drug Abuse","year":"1993"},{"key":"10.1016\/j.cct.2018.04.001_bb0215","series-title":"Paper presented at the Annual Meeting of the American Psychiatric Association, Miami Florida","article-title":"In search of a universal drug craving scale","author":"Somoza","year":"1995"},{"issue":"2","key":"10.1016\/j.cct.2018.04.001_bb0220","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.2003.10400007","article-title":"The clinical opiate withdrawal scale","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoactive Drugs"},{"issue":"24","key":"10.1016\/j.cct.2018.04.001_bb0225","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cct.2018.04.001_bb0230","article-title":"Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study","volume":"11","author":"Morden","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"issue":"3","key":"10.1016\/j.cct.2018.04.001_bb0235","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/135965350501000310","article-title":"Discordant conclusions from HIV clinical trials\u2014an evaluation of efficacy endpoints","volume":"10","author":"Hill","year":"2005","journal-title":"Antivir. Ther."},{"issue":"11","key":"10.1016\/j.cct.2018.04.001_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112328","article-title":"Methadone induction in primary care for opioid dependence: a pragmatic randomized trial (ANRS Methaville)","volume":"9","author":"Carrieri","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cct.2018.04.001_bb0245","series-title":"Adaptive Design Clinical Trials for Drugs and Biologics","author":"Center for Drug Evaluation and Research (CDER)","year":"2010"},{"issue":"2","key":"10.1016\/j.cct.2018.04.001_bb0250","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J. Sex Marital Ther."},{"issue":"6","key":"10.1016\/j.cct.2018.04.001_bb0255","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.cct.2018.04.001_bb0260","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1475-6811.1995.tb00092.x","article-title":"Sexual satisfaction in long-term heterosexual relationships: the interpersonal exchange model of sexual satisfaction","volume":"2","author":"Lawrance","year":"1995","journal-title":"Pers. Relat."},{"issue":"4","key":"10.1016\/j.cct.2018.04.001_bb0265","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/00926230290001448","article-title":"The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women","volume":"28","author":"Derogatis","year":"2002","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.cct.2018.04.001_bb0270","series-title":"National report: Apparent opioid-related deaths in Canada (January 2016 to March 2017)","year":"2017"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714418300351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714418300351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T01:14:58Z","timestamp":1660785298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714418300351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":54,"alternative-id":["S1551714418300351"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2018.04.001","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}